Skip to main content

Table 1 Clinical information about patients with RA and controls

From: Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways

Group RA OA HC
Sample size, n 83 67 88
Age, yr, mean ± standard deviation 58.30 ± 13.01 56.78 ± 13.98 55.73 ± 15.19
Sex, n    
 Male 22 17 20
 Female 61 50 68
Mean duration of disease, mo (range) 53.27 (1–456) 46.31 (1–323)
Stages of disease, n    
 Early RA (≤12 mo) 30   
 Late RA (>12 mo) 53   
Activity of disease, n    
 Remission (DAS28 < 2.6) 10
 Low (2.6 ≤ DAS28 ≤ 3.2) 16
 Moderate (3.2 < DAS28 ≤ 5.1) 45
 High (DAS28 > 5.1) 12
Manifestations of disease, n    
 Extraarticular 23
 Limited joint manifestations 60
Drug use before study
  1. RA rheumatoid arthritis, OA osteoarthritis, HC healthy controls, DAS28 28-joint Disease Activity Score